Aethlon Medical (NASDAQ:AEMD) Shares Break Below 200-Day Moving Average – Should You Sell?

Aethlon Medical, Inc. (NASDAQ:AEMD)’s stock price passed below its 200-day moving average during trading on Friday. The stock has a 200-day moving average of $7.10 and traded as low as $6.38. Aethlon Medical shares last traded at $6.45, with a volume of 40,818 shares.

Analysts Set New Price Targets

Several analysts have commented on AEMD shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Aethlon Medical in a research report on Friday, July 17th. Wall Street Zen raised shares of Aethlon Medical to a “sell” rating in a report on Saturday, August 8th. Finally, HC Wainwright reiterated a “neutral” rating on shares of Aethlon Medical in a research note on Friday, September 18th. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Reduce” and an average price target of $1.50.

Aethlon Medical Stock Down 2.7%

The company has a market cap of $4.59 million, a P/E ratio of -0.18 and a beta of 1.21. The firm’s 50-day moving average price is $3.44 and its 200-day moving average price is $7.10.

Aethlon Medical (NASDAQ:AEMD) last issued its earnings results on Thursday, August 13th. The medical equipment provider reported ($4.02) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($3.92) by ($0.10). As a group, analysts forecast that Aethlon Medical, Inc. will post -5.74 earnings per share for the current year.

Aethlon Medical Company Profile

Aethlon Medical, Inc is a clinical-stage medical device company focused on developing therapeutic technologies for cancer and life-threatening viral infections. The company’s lead product is the Hemopurifier, an investigational extracorporeal blood filtration device designed to selectively remove certain disease-causing particles, including tumor-derived exosomes and viruses, from the bloodstream.

The Hemopurifier is being evaluated as a potential adjunct to existing treatments. In oncology, the technology is intended to remove exosomes that may contribute to tumor progression and immune suppression.